BMS disappoints in late-stage liver cancer study; Vivus gets AdComm date for Qnexa review;

 @FierceBiotech: Here's the full list of the 40+ reports we published this year: List. 15 blockbuster contenders was most viewed of 2011. | Follow @FierceBiotech

 @RyanMFierce: BMS missed the mark in its late-stage study of brivanib for liver cancer, but $BMY not giving up. Report | Follow @RyanMFierce

 @FierceMedDev: Smiths Medical starts nationwide vlntry recall of certain Bivona neonatal, pediatric and FlexTend tracheotomy tubes. Release | Follow @FierceMedDev

> Bristol-Myers Squibb ($BMY) struck out in a late-stage trial for the liver cancer drug brivanib, failing to show that the drug could improve overall survival compared with placebo, but the drug powerhouse plans to forge ahead with the program, with a trio of trials testing the drug in other groups of liver cancer patients in the works. Article

> SkyePharma faces more delays on the European approval decision for its inhaled asthma treatment Flutiform because member states couldn't reach a consensus on the approval process. The U.K.-based drug delivery company now expects a 6- to 9-month delay on the approval. Report

> Merck ($MRK) has ended an Alzheimer's partnership with Acumen Pharmaceuticals, giving back rights to the developer for anti-ADDL antibodies and diagnostics. Item

> Albany, NY-based AMRI ($AMRI) announced that it has cut workers as it winds down internal R&D and focuses on its manufacturing business and providing contract services. The number of workers being let go was not disclosed in the company's announcement Thursday. Release

> Vivus ($VVUS) said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee is slated to meet Feb. 22 to review the Mountain View, CA-based developer's application for approval of the diet drug Qnexa. The FDA action date on the application is April 17. Release

> South San Francisco, CA-based Poniard Pharmaceuticals' ($PARD) shares took a hit after its merger pact with Seattle-based biotech Allozyme fell through. Bloomberg reported that the deal couldn't get done because the combined company's shares wouldn't qualify for listing. Report

> ViroPharma ($VPHM) has paid $7.5 million upfront a deal that gives the Exton, PA-based company an option to buy Meritage Pharma, a San Diego developer of a drug against chronic inflammatory disorder of the esophagus. Announcement

Pharma News

 @FiercePharma: Merck leads 2011's list of job-cutting drugmakers. Story | Follow @FiercePharma

> EMA blesses ovarian cancer use for Roche's Avastin. Report

> Big Pharma buybacks, spinoffs cater to investors. Piece

> Drug shortages dominate 2011 headlines. Story

> Merck leads 2011's list of job-cutting drugmakers. Article

> European crisis crimps pharma's finances. Report

And Finally... Happy holidays and a big thank you to our subscribers for reading FierceBiotech!

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.